Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dotmatics Informatics Selected to Enhance Research at Moulder Center for Drug Discovery

Published: Friday, January 25, 2013
Last Updated: Friday, January 25, 2013
Bookmark and Share
The Dotmatics platform is an integrated suite of software specifically designed to maximise efficiency in data transfer between research institutes, collaborators and CROs.

"After a thorough review of the commercially available software packages for sharing and exploiting the fruits of drug discovery research, it became clear that the Dotmatics platform represented not only the best configuration, but also the most comprehensive package available" said Dr. Magid Abou-Gharbia, Associate Dean for Research and Director of the Moulder Center. "In building our capacity at the Moulder Center for Drug Discovery Research we are focused on efficiently generating research data using a host of technologies and tools. The combination of Browser, Vortex and StudiesNotebook are key solutions which will allow our scientists to quickly triage, integrate and analyze data from multiple sources, speeding the pace and efficiency of research. These advantages afford our scientists increased opportunity to improve the health of patients through the discovery of new therapeutic agents."

The migration of The Moulder Center for Drug Discovery Research's legacy database to the Dotmatics platform will have a positive and dramatic impact on research workflow. Dr. Abou-Gharbia continued “Researchers at our center will benefit from the advanced data querying, analysis and reporting tools provided by this high end informatics platform. In addition, the secure web-based deployment of Dotmatics software will allow our external collaborators to easily access their data while maintaining safeguards against the release of data from unrelated programs. Our adoption of the Dotmatics system provides The Moulder Center with cutting edge Cheminformatics and database capabilities.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!